[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597018":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":32,"centralContacts":36,"locations":41,"responsibleParty":59,"collaborators":27,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":27,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":27,"enrollmentInfo":69,"targetDuration":27,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":27,"overallStatus":44,"whyStopped":27,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Eligible for surgery or LITT-Surveillance","EXPERIMENTAL","Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.",[13,14],"Procedure: Surgery","Procedure: LITT",{"label":16,"type":10,"description":11,"interventionNames":17},"Eligible for surgery or LITT-SRS2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Ineligible for surgery or LITT-SRS2",[13,14],[22,28],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"PROCEDURE","Surgery","Participants will initially undergo craniotomy and surgical resection of lesions or LITT",[16,9,19],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"LITT","Participants will undergo 4-core stereotactic biopsy and LITT by experienced neurosurgeons with specific expertise.",[16,9,19],[33],{"name":34,"affiliation":5,"role":35},"Subha Perni, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":27,"email":40},"CONTACT","713-563-2543","sperni@mdanderson.org",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"The University of Texas M. D. Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-95.36327,29.76328,{"lat":54,"lon":53},[57,58],{"name":34,"role":38,"phone":39,"phoneExt":27,"email":40},{"name":34,"role":35,"phone":27,"phoneExt":27,"email":27},{"type":60,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100597018","phase-2-laser-interstitial-thermal-therapy-litt-or-surgery-and-adjuvant-reirradiation-for-recurrent-brain-metastases-lasar-beam-100597018",false,"NCT07053033","Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Willingness to comply with all study procedures and availability for the duration of the study.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study.\n* Karnofsky performance status ≥ 60.\n* Radiographic concern for progression of a solid tumor brain metastasis that has received prior stereotactic radiosurgery ≥ 3 months prior to study enrollment.\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥5 mm with MRI scan.\n* Have active tumor on pathology from surgery\u002FLITT for this lesion.\n* Able to safely undergo MRI imaging.\n* Acceptable candidate for SRS2 per treating physician and multidisciplinary conference consensus.\n* Have no radiographic evidence of leptomeningeal disease on radiology report or neuro-radiologist review.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. All female patients between the onset of menses and 55 years will receive a pregnancy test prior to SRS2 unless the patient presents with an applicable exclusionary factor which may be one of the following:\n* Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n* History of hysterectomy or bilateral salpingo-oophorectomy.\n* Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n* History of bilateral tubal ligation or another surgical sterilization procedure.","ALL","18 Years",{"count":70,"type":71},155,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).",[77],"Brain Metastases","2026-03-05",{"date":80,"type":81},"2026-03-09","ACTUAL",{"date":83,"type":81},"2026-01-01",{"date":85,"type":71},"2028-12-30",{"name":5,"class":6},1]